PROTALIX BIOTHERAPEUTICS, INC. (PLX)

[wgg2]

Spideyboy, I would appreciate your help in clarifying how the PRX-115 phase one trial for severe gout is conducted. In the 3/21/2023 release it states: The trial is a single ascending dose (SAD) study with up to seven cohorts, and patients are being randomized 3:1 to receive a single intravenous (IV) dose of PRX-115 or a placebo. It says a patient can get up to seven treatments (I assume if needed). Then what does the word single mean later in the release? How frequently might the "up to 7 cohorts" be administered? Even though phase one trials are not to determine effectiveness, considering the nature of gout, it seems to me they will know rather quickly if it is effective or not. Agree? As of last week, they stated that they have 9 patients already being treated. If this works, this is another major market opportunity since there is little out there to treat severe gout. Thanks.